STK11 and non-small cell lung carcinoma: In a single-arm, phase 2 trial of sotorasib in patients with KRASG12C-mutated, previously treated NSCLC patients, the ORR was 37.1% (95% CI: 28.6-46.2).196 The exploratory analysis of this trial evaluated the impact of cooccurring mutations in STK11, KEAP1, and TP53: the ORR in patients with TP53 mutations was 39%, whereas it was 40% in those with STK11 mutations and 20% in those with KEAP1 mutations.